Connect with us

Hi, what are you looking for?


Biotech stock Prometheus Biosciences opened 70% up today: here’s why

Prometheus Biosciences Inc (NASDAQ: RXDX) opened about 70% up on Monday after Merck & Co Inc (NYSE: MRK) said it will buy the biotechnology company for $10.8 billion.

What’s in it for Merck & Co?

The all-cash agreement values each share of Prometheus Biosciences at $200 – over a 75% premium on the price at which the biotech stock ended last week.

With the said acquisition, Merck hopes to expand its footprint in immunology. According to its CEO Robert M. Davis:

This transaction adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade.”

The pharmaceutical giant has picked Morgan Stanley as its financial advisor for this deal. Merck shares are slightly in the red today.

What’s in it for Prometheus Biosciences?

The announced transaction will close in the third quarter of the current year as long as it receives approval from the shareholders and meet other closing conditions. In the press release, Prometheus’ CEO Mark McKenna said:

This agreement with Merck allows Prometheus to maximise the potential for PRA023, while continuing to apply our technology and expertise to fuel further discoveries to address the needs of patients with immune disorders.

PRA023 – its treatment for ulcerative colitis and Crohn’s disease is currently under development.

In February, Prometheus Biosciences reported a slightly narrower-than-expected loss for its fiscal fourth quarter. Its revenue, though, came in shy of the Street estimates.

The post Biotech stock Prometheus Biosciences opened 70% up today: here’s why appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.